about
Chronic thromboembolic pulmonary hypertension: role of medical therapyChronic thromboembolic pulmonary hypertensionTreatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry.Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHINLong-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry.Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.The phenomenon of latent pregnancy and cancer.The phenomenon of latent pregnancy and cancer.Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic.Risk factors for chronic thromboembolic pulmonary hypertension.Macitentan and morbidity and mortality in pulmonary arterial hypertension.Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry.Hemodynamic instability after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension correlates with cytokine network hyperstimulation.Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.Implementation of a new programme for the surgical treatment of CTEPH in the Czech Republic--Pulmonary endarterectomy.Effect of macitentan on hospitalizations: results from the SERAPHIN trial.Enzyme pattern of macrophages in the course of inflammation.Cellular inflammatory response. Findings in patients with neurological diseases.Amyotrophic lateral sclerosis. Abnormal cellular inflammatory responseThe course of a model cutaneous inflammation in the scapuloperoneal syndrome and in systemic neuromuscular diseasesAre pulmonary artery pulsatility indexes able to differentiate chronic pulmonary thromboembolism from pulmonary arterial hypertension? An echocardiographic and catheterization studyFunctional variants of eNOS and iNOS genes have no relationship to the portal hypertension in patients with liver cirrhosisSimple detection of the lupus erythematosus cell phenomenon
P50
Q26825088-CCC112CF-28EC-41B9-9DB4-73D383BAA799Q27014135-6FC96D97-A98A-438B-8D2D-A365C46B15E4Q33156379-C28CAD58-561A-4752-A362-8D2119A9F9FFQ33589653-10C2C097-41AC-4162-84AF-5EC0C37C8894Q34666291-02EE5C36-9FCD-4297-A1AD-DE1250281EFFQ35120770-5E9699F0-3CFF-4EC8-8BF7-548D739B66A3Q35986352-BA9E0051-6A1E-44BD-BC7B-A187C30372A8Q35986356-256C697B-D675-487B-8DCF-55087C820A17Q36332690-9AC4D0F8-ED13-48FA-8EC0-4F49D53AA479Q40941203-018610E1-70D1-43F3-A881-5863912D1928Q41143611-FD1AAF3E-73C4-43EF-8D96-C464D381EFE8Q41266185-D3B813EB-9D62-4010-A33A-2769CA36EDAEQ41323694-92EC2B04-EE3B-4DED-B767-5F218B276BE7Q43838385-A661A74D-F143-4D0F-B169-24B1F360FBA2Q44236882-BA6E4B0D-BF86-4F38-BC66-755A2A9A307DQ44343572-8F6C7F1B-1302-4C68-B1B8-DFC6B242A073Q44966770-E4099738-17BA-4301-ABC5-B695DC63A72BQ46013699-9351D429-88CC-4666-9B65-693F1F24FDE7Q46126985-A39EAF1D-3995-4DD2-B912-4E313BA53BA5Q46191143-7D248BC3-D840-4A7E-937B-7AF0D82C1BB6Q46201831-9196247D-DE85-4BF7-9628-D90D5E1943D7Q46318660-FF232A71-0993-4EFE-893D-4283DFC5BCEEQ46466513-27CBDB2B-56EA-48D0-B40C-6162D0F79DFCQ47799455-8C4314C2-B394-450D-8E66-2B497CC07CEDQ48561563-9B4243FF-8DE3-4831-ABA4-BA0F06F05261Q68676317-A12EF2AD-1BC9-48B6-B5F1-045F3484B03FQ70031771-61E66128-E7BC-4AEE-A58A-2859E4D89B03Q85209283-24A28C7F-3815-45F1-9D11-B0F6BB91C00DQ86241401-73364371-5A6F-4066-8E12-F0BF70032834Q93725967-E795157F-5D5B-479A-B6D1-4F9AD728190F
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Pavel Jansa
@ast
Pavel Jansa
@en
Pavel Jansa
@es
Pavel Jansa
@nl
Pavel Jansa
@sl
type
label
Pavel Jansa
@ast
Pavel Jansa
@en
Pavel Jansa
@es
Pavel Jansa
@nl
Pavel Jansa
@sl
prefLabel
Pavel Jansa
@ast
Pavel Jansa
@en
Pavel Jansa
@es
Pavel Jansa
@nl
Pavel Jansa
@sl
P214
P1053
O-2302-2017
P106
P1153
7005346938
P1343
P19
P21
P214
P31
P3829
P496
0000-0002-3711-7064
P569
1971-11-30T00:00:00Z
P691
jo2008427138
P734
P735
P7859
viaf-84197397